ArticleMayo Clinic proceedings2019
Elevated Vancomycin Trough Levels in a Tertiary Health System: Frequency, Risk Factors, and Prognosis.
Article in Mayo Clinic proceedings, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Protein binding of vancomycin in a large mixed patient population at a university hospital.Antimicrobial agents and chemotherapy · 2026Article
- Reversible Severe Cardiomyopathy Associated With Supratherapeutic Vancomycin Levels: A Case Report.Cureus · 2025Article
- Correlation Between Vancomycin Trough Concentrations and C-Reactive Protein in Neonates: A Retrospective Observational Study from a Tertiary Hospital in China.Infection and drug resistance · 2025Article
- Electrospun Chitosan-Based Nanofibrous Coating for the Local and Sustained Release of Vancomycin.ACS omega · 2024Article
- Medication-Related Adverse Events and Discordancies in Cystatin C-Based vs Serum Creatinine-Based Estimated Glomerular Filtration Rate in Patients With Cancer.JAMA network open · 2023Article
- Vancomycin-Associated Acute Kidney Injury: A Narrative Review from Pathophysiology to Clinical Application.International journal of molecular sciences · 2022Review
- Vancomycin-Associated Tubular Casts and Vancomycin Nephrotoxicity.Kidney international reports · 2021Article
- Prediction of Vancomycin Levels Using Cystatin C in Overweight and Obese Patients: a Retrospective Cohort Study of Hospitalized Patients.Antimicrobial agents and chemotherapy · 2020Observational
- Vancomycin in ICU Patients with Gram-Positive Infections: Initial Trough Levels and Mortality.Therapeutics and clinical risk management · 2020Article
- Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
objectiveTo investigate the frequency of, risk factors for, and outcomes after elevated levels of vancomycin. PATIENTS AND
methodsWe identified hospitalizations among 21,285 individuals in which intravenous vancomycin was given between August 29, 2007, and October 10, 2014. We investigated frequency and risk factors for elevated vancomycin levels (trough levels >30 mg/L) as well as associations with subsequent acute kidney injury (AKI), length of stay, and in-hospital mortality.
resultsAmong the 21,285 patients, the mean age was 62.9 years, and 10,478 (49.2%) were female. Trough levels of vancomycin were checked in 7422 patients, and 755 elevated levels were detected. Compared with patients with trough levels checked but no elevated levels found, those with elevated levels had longer duration of vancomycin therapy (median, 6.0 days vs 3.4 days; P<.001) and slightly higher doses (mean, 1.72 g vs 1.58 g; P<.001). Patients with higher body mass index or lower estimated glomerular filtration rate had more elevated levels. In propensity-matched analyses, patients had higher risk of incident AKI after elevated levels compared with patients without elevated levels (hazard ratio, 1.55; 95% CI, 1.09-2.20; P=.02), as well as longer subsequent length of stay (relative risk, 1.14; 95% CI, 1.02-1.28; P=.03) but similar in-hospital mortality.
conclusionIn this study, elevated vancomycin levels were common, particularly in patients with higher body mass index and lower estimated glomerular filtration rate, and were associated with greater subsequent AKI and length of stay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.